Sugi Predict

Sugi Predict / Compounds / SCHEMBL433140

SCHEMBL433140

SCHEMBL433140

c1ccc(C([SiH2]O[SiH2]C(c2ccccc2)c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DPP4 P27487 2/20 0.39
▸ F2 P00734 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ HTR2A P28223 1/20 0.36
▸ TAAR1 Q96RJ0 1/20 0.36
▸ CYP2D6 P10635 2/20 0.35
▸ SRC P12931 1/20 0.35
▸ CYP1A2 P05177 1/20 0.34
▸ PKM P14618 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ LMNA P02545 2/20 0.33
▸ HRH1 P35367 1/20 0.33
▸ MTOR P42345 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ GRM7 Q14831 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ SLC6A2 P23975 1/20 0.33
▸ SLC6A4 P31645 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL514830 0.82 DPP4 (0.31) DPP4F2TSHR
SCHEMBL587674 0.79 DPP4 (0.36) DPP4F2TSHRHTR2ATAAR1
SCHEMBL704150 0.79 KMT2A (0.40) DPP4F2TSHRHTR2ATAAR1
SCHEMBL17865441 0.77 DPP4 (0.35) DPP4F2TSHRHTR2ATAAR1
SCHEMBL703093 0.77 SCN4A (0.38) DPP4F2TSHRHTR2ATAAR1
SCHEMBL705271 0.75 TAAR1 (0.37) DPP4TSHRTAAR1CYP2D6LMNA
SCHEMBL7029688 0.74 SRC (0.35) DPP4F2TSHRCYP2D6SRC
SCHEMBL11905375 0.74 CYP2D6 (0.38) DPP4F2TSHRCYP2D6SRC
SCHEMBL17865454 0.74 SRC (0.40) CYP2D6SRCNPSR1LMNAMAPK1
SCHEMBL242576 0.74 LMNA (0.40) HTR2ATAAR1LMNAHRH1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 393 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4116338-B1 HYDROPHILIC POLYMERIC PARTICLES AND METHODS FOR MAKING SAME LIFE TECHNOLOGIES CORP (US) 2025-06-11 — — EP claimed
US-10834919-B2 Cryopreservation instrument and method of using same RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL (US) 2020-11-17 — — US claimed
US-20170280708-A1 CRYOPRESERVATION INSTRUMENT AND METHOD OF USING SAME RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL 2017-10-05 — — US claimed
CN-104245745-B Hydrophilic polymer particles and method for producing same 生命技术公司 2017-03-29 — — CN claimed
WO-2016040063-A1 CRYOPRESERVATION INSTRUMENT AND METHOD OF USING SAME THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL (US) 2016-03-17 — — WO claimed
CN-104245745-A Hydrophilic polymer particles and method for producing same LIFE TECHNOLOGIES CORP 2014-12-24 — — CN claimed
US-8334099-B2 Nucleic acid amplification using a reversibly modified oligonucleotide BI WANLI (US) 2012-12-18 — — US claimed
EP-2049689-B1 NUCLEIC ACID AMPLIFICATION USING A REVERSIBLY MODIFIED OLIGONUCLEOTIDE BI WANLI (US) 2011-12-21 — — EP claimed
US-20100021970-A1 Nucleic Acid Amplification Using a Reversibly Modified Oligonucleotide BI WANLI 2010-01-28 — — US claimed
EP-2049689-A2 NUCLEIC ACID AMPLIFICATION USING A REVERSIBLY MODIFIED OLIGONUCLEOTIDE Bi, Wanli (US) 2009-04-22 — — EP claimed
WO-2008016562-A2 NUCLEIC ACID AMPLIFICATION USING A REVERSIBLY MODIFIED OLIGONUCLEOTIDE BI WANLI (US) 2008-02-07 — — WO claimed
EP-3494996-B1 ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS AGENSYS INC (US) 2026-04-15 — — EP disclosed
US-20260034234-A1 ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS AGENSYS, INC. (US) 2026-02-05 — — US disclosed
US-20260000604-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-191P4D12 ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF AGENSYS, INC. (US) 2026-01-01 — — US disclosed
US-12496353-B2 Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway SEAGEN INC. (US) 2025-12-16 — — US disclosed
EP-0485517-A1 SYNTHESIS OF GLYCOSIDES HAVING PREDETERMINED STEREOCHEMISTRY YALE UNIVERSITY (US) 1992-05-20 — — EP disclosed
US-5104982-A ROUTE TO GLYCALS IN THE ALLAL AND GULAL SERIES YALE UNIVERSITY (US) 1992-04-14 — — US disclosed
EP-0450823-A2 The conversion of amines to hydroxylamines YALE UNIVERSITY (US) 1991-10-09 — — EP disclosed
EP-0448412-A2 A route to glycals in the allal and gulal series YALE UNIVERSITY (US) 1991-09-25 — — EP disclosed
WO-1991002739-A1 SYNTHESIS OF GLYCOSIDES HAVING PREDETERMINED STEREOCHEMISTRY YALE UNIVERSITY (US) 1991-03-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12496353-B2 Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway MTOR, RICTOR, PIK3R5 DPP4 3310/4885F2 4854/4885TSHR 2706/4885
US-20260000604-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-191P4D12 ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF CD44, CA12, H1-10 DPP4 1197/4885F2 3255/4885TSHR 2385/4885
US-20260034234-A1 ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS IGSF11, ARID2, DYNLL2 DPP4 3740/4885F2 4786/4885TSHR 3069/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.